jRCT2080223829已完成1 期
A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-438ASA tablet and Single Oral Dose of TAK-438 tablet plus Aspirin Enteric-Coated tablet (Study 1) and the Food Effect of Single Oral Dose of TAK-438ASA tablet (Study 2) in Healthy Adult Male Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 276
- 试验地点
- 1
- 主要终点
- AUClast for Free Base of TAK-438 (TAK-438-F)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized, Open-Label, 2x2 Crossover
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 60age old under（—）
- 性别
- Male
入选标准
- •In the opinion of the investigator or sub-investigator, participants are capable of understanding the procedures required for the study and complying with its requirements
- •Participants sign and date an informed consent form by themselves prior to the initiation of any study procedures
- •Japanese healthy men aged >= 20 and =< 60, inclusive, at the time of consent
- •Body weight >= 50 kg as well as body mass index (BMI) >= 18.5 kg/m^2 and =< 25.0 kg/m^2 at screening test
排除标准
- •Participants who received study drug within 16 weeks (112 days) prior to the start of study treatment in Period 1
- •Participants who received TAK-438 or aspirin in a previous study
- •Staffs at the study site and their family, or participants who depend on the study-related staffs at the study site (e.g., husband and wife, parents, children, brothers and sisters), or participants who may be constrained to consent to the study
- •Participants with uncontrolled and clinically significant neurological, cardiovascular, lung, hepatic, renal, metabolic, gastrointestinal, urinary or endocrine disease, or other abnormalities (except for diseases investigated) that might affect the study participation or impact the results of the study
- •Participants with a previous or current history of aspirin asthma (asthmatic attack induced by non-steroidal anti-inflammatory drugs, etc.)
- •Participants with hypersensitivity for components of TAK-438 tablet or aspirin enteric-coated tablet, or salicylic acid-based products
- •Positive result in urinary test for illegal drug abuse at screening
- •Participants who have a history of illegal drug abuse or alcoholism within the past 2 years prior to the screening visit, or who are not willing to refrain from alcohol consumption and drug use during the study period
- •Participants who ingested a medicine, a supplement or food forbidden to be used in combination during the specified time period.
- •Participants with a current history or recent episodes (within the past 6 months) of gastrointestinal diseases (malabsorption, gastroesophageal reflux, peptic ulcer disease, erosive oesophagitis), frequent (at least once per week) heartburn or surgical intervention that might affect drug absorption
- •Participants with a history of cancer, except for basal cell carcinoma in remission for >= 5 years prior to Day 1
- •Positive results at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or serological test for syphilis
- •Participants who have difficulties in blood draw from peripheral veins
- •Participants who had >= 200 mL of whole blood drawn within 4 weeks (28 days) prior to the start of study treatment in Period 1 or who had >= 400 mL of whole blood drawn within 12 weeks (84 days) prior to the start of study treatment in Period 1
- •Participants who had a total of >= 800 mL of whole blood drawn within 52 weeks (364 days) prior to the start of study treatment in Period 1
- •Participants who had blood components drawn within 2 weeks (14 days) prior to the start of study treatment in Period 1
- •Clinically significant abnormalities in electrocardiogram at screening or admission (Day -1)
- •Participants with abnormal laboratory parameters suggestive of clinically significant underlying diseases or who have abnormal values in the following measures at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) over the upper limit of normal
- •Participants who are unlikely to comply with the protocol or deemed ineligible due to other reasons by the principal investigator or other investigators.
结局指标
主要结局
AUClast for Free Base of TAK-438 (TAK-438-F)
时间窗: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438-F)
AUClast for Unchanged Aspirin
时间窗: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin
Cmax for TAK-438F
时间窗: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Maximum Observed Plasma Concentration for TAK-438F
Cmax for Unchanged Aspirin
时间窗: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Maximum Observed Plasma Concentration for Unchanged Aspirin
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Bioequivalence evaluation of test and reference formulations of Voriconazole 200 mg tablets administered to 38 healthy volunteers after single dose (2-Period, 2-Treatment, 2-Sequence, 2-Way, Crossover Study under fasting condition)Bioequivalence studyBioequivalenceTCTR20181220006Bio-innova and Synchron.Co.,Ltd38
招募中
不适用
Bioequivalency study of two different Metformin formulationsIRCT20111107008022N7Reihaneh Pharmaceutical Company24
尚未招募
Unknown
Bioequivalence study of two different Ciprofloxacin formulationsIRCT20111107008022N13Zagrous Darou Pharmaceutical Company24
尚未招募
不适用
Bioequivalence study of two different Fenofibrate formulationsIRCT20111107008022N10Aviccena Pharmaceutical Company24
招募中
不适用
Bioequivalency study of two different Pantoprazole formulationsHealth volunteers.IRCT20111107008022N8Exir Pharmaceutical Company24